Breath Signatures of Antiseizure Medication Response and Tolerability in Adults With Epilepsy
CNS Neuroscience & Therapeutics · 2026-10 · 32 (10)
DOI: 10.1002/cns.71169 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 28.09.2026. Verfasst von Kai Fricke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lotte und Adolf Hotz-Sprenger Stiftung, Schwyzer-Winiker Stiftung, Uniscientia Foundation.
Abstract (Originalsprache)
Purpose
Achieving seizure control without intolerable adverse effects remains a major challenge in adult epilepsy, and serum concentrations of antiseizure medications correlate poorly with clinical outcomes. Metabolic processes influencing treatment response are not captured by blood monitoring. This study evaluates whether exhaled breath metabolomic profiles reflect treatment response and adverse effects in adults receiving antiseizure therapy, using epilepsy as a model for pharmacodynamic phenotyping. Materials and Methods A single‐center observational cohort of 117 adults provided 127 breath samples during stable antiseizure treatment. Exhaled breath samples were analyzed using secondary electrospray ionization high‐resolution mass spectrometry. Machine‐learning models with nested cross‐validation were used to classify treatment response and adverse effects, and pathway‐level analyses were performed to provide biological context. Findings were compared with an independent, predominantly pediatric cohort analyzed using the same workflow.
Results
Breath metabolomic profiles distinguished responders from nonresponders and individuals with and without adverse effects, whereas serum drug concentrations showed no meaningful association. Classification models achieved areas under the curve of 0.84 for treatment response and 0.88 for adverse effects, with good calibration. Pathway‐level alterations were directionally consistent across cohorts.
Conclusion
Breath metabolomics supports a non‐invasive approach to pharmacodynamic phenotyping that captures treatment‐related metabolic states not reflected by serum drug concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
- Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- University Children's Hospital Basel, Basel, Switzerland.
- Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
ORCID-Profile: Kai Fricke, Diego Manuel Baur, Kapil Dev Singh, Noriane Andrina Sievi, Marco Di Donato, Anton Schmick, Silvia Ulrich, Pablo Sinues, Marian Galovic
Förderung
- Lotte und Adolf Hotz-Sprenger Stiftung
- Schwyzer-Winiker Stiftung
- Uniscientia Foundation
- Lunge Zürich
- Fondation Botnar
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Fricke, K., Baur, D. M., Singh, K. D., Schmidt, F., Müsch, K., Sievi, N. A., Di Donato, M., Schmick, A., Ulrich, S., Sinues, P., Galovic, M., & Kohler, M. (2026). Breath Signatures of Antiseizure Medication Response and Tolerability in Adults With Epilepsy. CNS Neuroscience & Therapeutics, 32(10). https://doi.org/10.1002/cns.71169
Vancouver
Fricke K, Baur DM, Singh KD, Schmidt F, Müsch K, Sievi NA, et al. Breath Signatures of Antiseizure Medication Response and Tolerability in Adults With Epilepsy. CNS Neuroscience & Therapeutics. 2026;32(10). doi:10.1002/cns.71169
BibTeX
@article{Fricke2026,
author = {Fricke, Kai and Baur, Diego Manuel and Singh, Kapil Dev and Schmidt, Felix and Müsch, Kathrin and Sievi, Noriane Andrina and Di Donato, Marco and Schmick, Anton and Ulrich, Silvia and Sinues, Pablo and Galovic, Marian and Kohler, Malcolm},
title = {Breath Signatures of Antiseizure Medication Response and Tolerability in Adults With Epilepsy},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {10},
doi = {10.1002/cns.71169}
}
EUVIMED